Fiona Levy MD Appointed Medical Director of Cohen Children’s Medical Center

Fiona Levy MD will oversee the hospital’s medical staff, lead staff engagement and development while participating in community outreach efforts for the largest provider of pediatric health services in New York State.

Cohen Children’s has been rated the No. 1 children’s hospital in the state and earned top national rankings for exceptional care in nine pediatric specialties, according to US News & World Report’s 2021-2022 Best Children’s Hospitals. Dr. Levy, who will also serve as vice president for Northwell’s pediatric service line, succeeds Peter Silver, MD, who was recently named senior vice president and chief quality officer at the health system.

“Having Dr. Levy back here at Cohen Children’s will be such a great asset for us,” said Charles Schleien, MD, senior vice president and chair of pediatric services at Northwell. “Her experience in clinical and administrative duties, as well as her intellect, personality and ability to get through difficult issues will be recognized by everyone in our hospital as a major positive.”

Fiona Levy MD rejoins Cohen Children’s after a stint at NYU Langone Health’s Hassenfeld Children’s Hospital, where she served as executive director of the Sala Institute for Child and Family Centered Care since 2014. She also was vice chair of clinical affairs for the Department of Pediatrics at the NYU School of Medicine.

From 2011-2014, Dr. Levy served as an attending physician in the intensive care unit at Cohen Children’s as well as the hospital’s vice president and chief quality officer. Dr. Levy began her medical career at children’s hospitals in St. Louis, MO, and Dallas, TX.

Fiona Levy MD earned her medical degree from New York Medical College in Valhalla, a master of business administration from Washington University in St. Louis, MO, and a bachelor of science in chemistry from Wellesley College, MA. She completed her residency at SUNY Health Scirnce Center in Syracuse and a fellowship at Children’s Hospital and Medical Center in Seattle, WA.

“We are thrilled to welcome back Dr. Levy. She brings with her many years of patient-focused care with an emphasis on exemplary quality outcomes,” said Carolyn Quinn, RN, senior vice president of pediatrics at Northwell and executive director of Cohen Childen’s Medical Center. “Dr Levy is a welcomed addition to our executive leadership team.”

In addition, Nancy Palumbo, MD, who served as the hospital’s interim medical director since January, has been promoted to associate medical director for Cohen Children’s. Prior to that, Dr. Palumbo was chief of hospital medicine. She joined Cohen Children’s in 2008.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.